CLAIMS

1. A powder formulation characterized in that the formulation comprises~~ing~~
~~(i)~~ micronized particles with a mean particle diameter of 20 μm or less comprising pirfenidone
~~(i-1) a drug showing a side effect of drug-induced photodermatosis~~ and
~~(i-2)~~ an excipient, and
~~(ii)~~ a carrier with a mean particle diameter of 10 to ~~-~~200 μm.

~~2. The powder formulation according to Claim 1, wherein the drug showing a side effect of drug-induced photodermatosis is 1 or 2 or more selected from the group consisting of antibiotics, anticancer drug, antiepileptic drug, antidepressant, antifungal, antihistamine, antimalarial, gout drug, psychotropic drug, cardiovascular remedy, diuretic, antilipemic, non-steroid anti-inflammatory agent, phototherapy agent, letinoid, and pulmonary fibrosis treating agent.~~

~~3. The powder formulation according to Claim 1, wherein the drug showing a side effect of drug-induced photodermatosis is a pulmonary fibrosis treating agent.~~

~~4. The powder formulation according to Claim 1, wherein the drug showing side effects of drug-induced photodermatosis is pirfenidone.~~

2~~5~~. The powder formulation according to ~~any one of~~ Claims 1~~-4~~, wherein the micronized particle and the carrier form a complex.

3~~6~~. The powder formulation according to Claim 2~~5~~, wherein the~~a~~ particle diameter of the micronized particle is smaller than the~~a~~ mean particle diameter of the carrier.

4~~7~~. The powder formulation according to any one of Claims 1 to 3~~-6~~, wherein the excipient and/or the carrier is a~~are~~ saccharides.

58. The powder formulation according to Claim 47, wherein the saccharides isare lactose.

69. The powder formulation according to any one of Claims 1 to 3-6, wherein the excipient and/or the carrier is aare sugar alcohols.

710. The powder formulation according to eClaim 69, wherein the sugar alcohols isare erythritol.

811. The powder formulation according to any one of Claims 1 to 3-6, wherein the excipient is a macromolecular polymers.

912. The powder formulation according to any one of Claims 1 to 3-6, wherein the excipient is erythritol and the carrier is lactose.

1013. The powder formulation according to any one of Claims 1 to 9-12, wherein thea ratio between pirfenidonethe drug showing side effects of drug-induced photodermatosis and the excipient is in the range of 1:5000 to ~10:1 in weight ratio.

1114. The powder formulation according to any one of Claims 1 to 10-13, wherein the ratio between the micronized particle and the carrier is in the range of 1:100 to ~10:1 in weight ratio.

1215. The powder formulation according to any one of Claims 1 to 11-14, wherein thea mean diameter of the micronized particles is in the range of 1 to ~9 μm.

1316. The powder formulation according to any one of Claims 1 to 12-15, wherein the powder formulation is a transpulmonary inhalation formulation.

1417. The powder formulation according to Claim 14, wherein the drug-induced photodermatosis of pirfenidone has been reduced as compared with an oral administration formulation.

1518. A process for producing the formulation according to any one of Claims 1 to 14-17, wherein the micronized particles with a mean particle diameter of 20 μm or less comprising pirfenidone~~a drug showing side effects of drug-induced photodermatosis~~ and an excipient are mixed with a carrier having a particle diameter of 10 to ~200 μm.

1619. The process according to Claim 1518, wherein the micronized particles are prepared by mixing pirfenidone~~the drug showing side effects of drug-induced photodermatosis~~ and the excipient, and micronizing the mixture by a jet mill.

1720. The process according to Claim 1619, wherein the micronized particles and the carriers are mixed in a container made from nylon or polyethylene.

1821. The process according to any one of Claims 15 to 17~~18-20~~, wherein the micronized particle and the carrier form a complex.

~~22. An inhalation formulation obtained by the process according to any one of Claims 18-21.~~